SARA DONNELLY: Open Payments
NPI 1760761449 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,696 in 77 payments from 16 companies in 2025. Trend: 2023 $1,631 · 2024 $2,491 · 2025 $1,696
Food & beverage: $1,696
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $248 |
| Madrigal Pharmaceuticals | 10 | $203 |
| ABBVIE INC. | 13 | $202 |
| Celltrion USA Inc. | 9 | $145 |
| Intercept Pharmaceuticals, Inc. | 7 | $135 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $128 |
| Regeneron Healthcare Solutions, Inc. | 4 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $102 |
| Ipsen Biopharmaceuticals, Inc | 4 | $86 |
| AstraZeneca Pharmaceuticals LP | 3 | $81 |
Products named: REZDIFFRA, VEGZELMA, DUPIXENT, OCALIVA, XIFAXAN, ENTYVIO, LINZESS, IQIRVO.
Industry payments across CA — which companies pay providers there.
